Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Luvox CR Symptom Benefit Claims Draw DDMAC Warning

Executive Summary

An FDA warning letter to Jazz Pharmaceuticals citing a Luvox CR (fluvoxamine maleate) patient brochure continues an agency trend of targeting efficacy claims about individual symptoms of a broader disease state

You may also be interested in...



Jazz Buys Compliance Trouble With FazaClo Acquisition

The schizophrenia drug’s previous owner, Azur Pharma, produced a patient brochure that drew a warning letter FDA’s Office of Prescription Drug Promotion.

Rx Promotional Campaign Based On Individual Symptoms Gives FDA Allergic Reaction

Meda’s allergic rhinitis drug Astepro (azelastine) draws an FDA letter for a telephone sales script that focused on the drug’s effect on nasal congestion, which was not studied separately from its effect on other symptoms.

Patient Who Wouldn't Be Here Without Axcan's Photofrin Should Disappear Now, FDA Says

Web videos featuring overblown patient testimonials prove an easy target for DDMAC.

Related Content

Topics

UsernamePublicRestriction

Register

PS052461

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel